Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | ACE | P12821 | 4/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | MC5R | P33032 | 2/20 | 0.45 |
| ▸ | MC1R | Q01726 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16171805 | 1.00 | MME (0.51) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL14511422 | 1.00 | MME (0.51) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL14537029 | 0.87 | MME (0.52) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL13957286 | 0.87 | MME (0.62) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL16252303 | 0.87 | MME (0.52) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL24510711 | 0.87 | MME (0.52) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL16252292 | 0.87 | MME (0.62) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL22791879 | 0.87 | MME (0.52) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL21166945 | 0.87 | MME (0.52) | MMEACECPA1ACE2MMP9 | |
| SCHEMBL13707921 | 0.86 | HTR2A (0.54) | MMEACECPA1ACE2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | MME 3786/4885ACE 4369/4885CPA1 3497/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | MME 3786/4885ACE 4369/4885CPA1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.